Zydus Lifesciences to Acquire US Oncology Firm Assertio Holdings for $166.4 Million

Zydus Lifesciences will acquire US-based Assertio Holdings for $166.4 million, paying $23.50 per share. Assertio's product ROLVEDON® generated $68.23 million in turnover in 2025.

The Deal Details

Zydus Lifesciences, via its subsidiary Zara Merger Sub Inc., has signed a definitive agreement to buy US biopharmaceutical company Assertio Holdings. The total cost for the acquisition is around $166.4 million.

Under the deal, Zydus will start a tender offer to buy all outstanding Assertio shares for $23.50 each in cash. Assertio, now listed on Nasdaq, will be taken off the exchange once the transaction closes.

Strategic Importance

This acquisition is a key move for Zydus Lifesciences to strengthen its position in the US specialty oncology market. It gives Zydus a ready-made commercial platform, including Assertio's network of over 170 community oncology accounts and its main product, ROLVEDON® (eflapegrastim xnst).

This aligns with Zydus's long-term goal of developing specialized businesses worldwide, securing a stronger presence in a crucial regulated market.

Zydus's US Expansion Strategy

Zydus Lifesciences has a clear strategy to grow in regulated markets, especially the United States. This involves expanding products organically through approvals and market entry, as well as making strategic acquisitions to boost its product range and sales capabilities.

The company has previously acquired brands to build its US generics business, showing its commitment to seizing opportunities in this important market.

Key Impacts of the Acquisition

• Zydus Lifesciences gains better access to the US specialty oncology market.
• The company acquires Assertio's existing commercial network and customer ties.
• ROLVEDON® is set to become a core product in Zydus's US offerings.
• The deal is expected to close by Fiscal Year 2026-27, pending regulatory and shareholder approvals.
• Assertio Holdings will no longer be listed on Nasdaq.

Potential Deal Risks

The acquisition faces several conditions. If these are not met, including securing necessary regulatory approvals, the deal could be delayed or fall through.

Shareholder approval for the tender offer is not guaranteed, and Assertio could receive competing acquisition bids.

There's also a risk of shareholder lawsuits related to the deal, which could incur significant legal costs. Additionally, management focus might shift from daily operations.

Industry Context: US Market Focus

Major Indian pharmaceutical companies, including Sun Pharmaceutical Industries and Dr. Reddy's Laboratories, also have significant operations and interests in the US market. Sun Pharma generates substantial US revenue from generics and specialty areas like oncology, often growing through acquisitions. Dr. Reddy's also relies heavily on US revenue, focusing on complex generics and biosimilars, highlighting the sector's strong emphasis on this key market.

Looking Ahead

• Watch for the start of the tender offer, expected within five business days.
• Monitor the progress of closing conditions, including regulatory approvals.
• Track shareholder response and participation in the tender offer.
• Look for any news of competing acquisition bids for Assertio Holdings.